
Vertex Pharmaceuticals
OrganizationHeard in 22 episodes across 14 shows since Dec 2025
Vertex Pharmaceuticals Incorporated is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotechnology firms to utilize an explicit strategy of rational drug design rather than combinatorial chemistry. The company focuses on developing and commercializing therapies for treating serious diseases, notably cystic fibrosis.
Episodes
This week
Expert statements
Share of the conversation
Mentions of Vertex Pharmaceuticals per 1,000 mentions of anything, 7-day rolling, across the podcasts PodLume Trends follows.
Show the data
| Day | Share (7-day) | Mentions |
|---|---|---|
| Sep 2 | 0.01‰ | 1 |
| Sep 13 | 0.01‰ | 1 |
| Oct 16 | 0.01‰ | 1 |
| Oct 23 | 0.01‰ | 1 |
| Oct 28 | 0.02‰ | 1 |
| Oct 30 | 0.03‰ | 2 |
| Nov 2 | 0.03‰ | 1 |
| Nov 3 | 0.04‰ | 1 |
| Nov 6 | 0.03‰ | 2 |
| Nov 12 | 0.02‰ | 1 |
| Nov 13 | 0.02‰ | 1 |
| Nov 15 | 0.02‰ | 1 |
| Nov 20 | 0.02‰ | 1 |
Email alert
Email me when Vertex Pharmaceuticals comes up on a podcast
One email a week at most, with the new episodes that mention Vertex Pharmaceuticals. Free, no account needed, unsubscribe in one click.
What experts have said about Vertex Pharmaceuticals
7 statements · 4 positive · 3 neutral
Vertex agreed to acquire Crinetics for $10 billion in cash.
“Vertex has agreed to buy Crenex for $10 billion in cash.”
Open the episode · Micron and Sandisk Drop; SpaceX Rating; Crinetics SoarsListen at 3:54
The Crinetics acquisition will give Vertex entry into endocrinology.
“This will give Vertex an entry into the endocrinology market.”
Open the episode · Micron and Sandisk Drop; SpaceX Rating; Crinetics SoarsListen at 4:09
Vertex Pharmaceuticals agreed to acquire Kinetics Pharma for $85 per share.
“Vertex Pharmaceuticals agreeing to acquire kinetics Pharma for 85 bucks a share.”
Open the episode · Crinetics Gains on Vertex Deal, Solstice Acquire Element, Terawulf JumpsListen at 1:07
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Episodes
22 episodes featuring Vertex Pharmaceuticals, newest first
- Nov 20, 2026
AI valuations collide with inflation and market riskMad Money w/ Jim CramerNov 20, 2026 - Nov 15, 2026
Biotech investors weigh gene editing, MASH data and RAS riskBreaking BiotechNov 15, 2026 - Nov 13, 2026
Heart drug failures test genetics-led discoveryThe Readout LoudNov 13, 2026 - Nov 12, 2026
Biotech’s uncertainty creates disciplined investment opportunitiesThe Acquirers PodcastNov 12, 2026 - Nov 6, 2026
Election stakes meet biotech’s regulatory and pipeline risksBiotech HangoutNov 6, 2026 - Nov 6, 2026
Data-center backlash forces markets to rethink AI growthThe Compound and FriendsNov 6, 2026